var data={"title":"Cellular mechanisms of diastolic dysfunction","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Cellular mechanisms of diastolic dysfunction</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/contributors\" class=\"contributor contributor_credentials\">James P Morgan, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/contributors\" class=\"contributor contributor_credentials\">Wilson S Colucci, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/contributors\" class=\"contributor contributor_credentials\">Susan B Yeon, MD, JD, FACC</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;May 22, 2015.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately one-third of patients with symptomatic congestive heart failure have a normal ejection fraction and symptoms that are entirely or in large measure a result of diastolic dysfunction. Diastolic dysfunction is caused by one or more of the following abnormalities in cardiac structure:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypertrophy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fibrosis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Infiltrative diseases</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pericardial constriction</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Myocardial edema</p><p/><p>Functional cellular abnormalities of myocyte relaxation can also cause diastolic dysfunction, which is reversible and transient [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/1\" class=\"abstract_t\">1</a>]. Causes of impaired myocyte relaxation include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ischemia <span class=\"nowrap\">and/or</span> hypoxia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cellular calcium overload <span class=\"nowrap\">and/or</span> adenosine triphosphate (ATP) depletion</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Certain cardiovascular drugs, eg, digitalis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The hypertrophy process itself which alters the contractile and metabolic phenotype.</p><p/><p>The cellular mechanisms of myocardial relaxation are presented here. These mechanisms involve calcium and sodium movements that reverse the processes of excitation-contraction coupling and can be thought of as repolarization-relaxation coupling. The pathophysiology, clinical features, treatment, and prognosis of diastolic dysfunction are discussed separately. (See <a href=\"topic.htm?path=pathophysiology-of-heart-failure-with-preserved-ejection-fraction\" class=\"medical medical_review\">&quot;Pathophysiology of heart failure with preserved ejection fraction&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-heart-failure-with-preserved-ejection-fraction\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of heart failure with preserved ejection fraction&quot;</a> and <a href=\"topic.htm?path=treatment-and-prognosis-of-heart-failure-with-preserved-ejection-fraction\" class=\"medical medical_review\">&quot;Treatment and prognosis of heart failure with preserved ejection fraction&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EXCITATION-CONTRACTION AND REPOLARIZATION-RELAXATION COUPLING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Drugs, metabolic processes, or pathologic conditions may exert a positive or negative inotropic effect by influencing the movement of and sensitivity to calcium as part of the excitation-contraction coupling process. On the other hand, a positive or negative lusitropic (relaxation-enhancing) effect can result from changes in repolarization-relaxation coupling.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Role of calcium</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rapid changes in the intracellular levels of free ionized calcium regulate the contraction and relaxation of cardiac muscle. The modulation of calcium levels during systole and diastole occurs at several sites within the cell [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/2\" class=\"abstract_t\">2</a>]. The sarcoplasmic reticulum (SR) plays a central role in regulating contraction and relaxation of mammalian cardiac muscle. The SR serves as a releasable Ca<sup>2+</sup> store and regulates intracellular calcium levels during <span class=\"nowrap\">contraction/relaxation</span> cycles. Its function is coordinated by a set of Ca<sup>2+</sup> handling proteins, primarily the ryanodine receptor 2 (RYR2), which activates calcium release, and by the sarco(endo)plasmic reticulum Ca<sup>2+</sup> ATPase pump (SERCA2), which governs calcium re-uptake by the SR [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/3\" class=\"abstract_t\">3</a>]. </p><p>Contraction is initiated during myocyte activation. An inward calcium current occurs during the action potential, when the sarcolemmal voltage-dependent calcium channel opens, and calcium diffuses into the cell, driven by its 10,000-fold transmembrane concentration gradient (<a href=\"image.htm?imageKey=CARD%2F53118\" class=\"graphic graphic_figure graphicRef53118 \">figure 1</a>). This calcium influx triggers a much greater amount of calcium release from the SR via RYR2. Cytosolic calcium levels rise rapidly and calcium binds to its myofilament receptor on troponin C, activating contractile protein tension generation via the actin-myosin cross-bridge cycle (<a href=\"image.htm?imageKey=CARD%2F67388\" class=\"graphic graphic_figure graphicRef67388 \">figure 2</a>). (See <a href=\"topic.htm?path=excitation-contraction-coupling-in-myocardium\" class=\"medical medical_review\">&quot;Excitation-contraction coupling in myocardium&quot;</a>.)</p><p>For complete myocyte relaxation to occur, the cytosol must be largely cleared of calcium so that calcium dissociates from troponin C, and all tension-generating actin-myosin bonds must be lysed. The diastolic clearance of cytosolic calcium requires adenosine triphosphate (ATP) to fuel the SERCA2 and sarcolemma calcium ATPases, which transport calcium into the SR or across the sarcolemma, respectively (<a href=\"image.htm?imageKey=CARD%2F79802\" class=\"graphic graphic_algorithm graphicRef79802 \">algorithm 1</a>). Calcium removal may also occur via sodium-calcium exchange, a process of secondary active transport driven by the low intracellular sodium concentration.</p><p>Cardiac contractility and lusitropy may be altered by changing either the availability of intracellular calcium for activation or the responsiveness of the myofilaments to intracellular calcium (<a href=\"image.htm?imageKey=CARD%2F75235\" class=\"graphic graphic_table graphicRef75235 \">table 1</a> and <a href=\"image.htm?imageKey=CARD%2F63030\" class=\"graphic graphic_figure graphicRef63030 \">figure 3</a>) [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/2,4,5\" class=\"abstract_t\">2,4,5</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The availability of intracellular calcium is regulated by the sarcolemma and sarcoplasmic reticulum; these processes can be functionally monitored by means of the action potential and calcium transient, respectively (<a href=\"image.htm?imageKey=CARD%2F66739\" class=\"graphic graphic_figure graphicRef66739 \">figure 4</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Calcium responsiveness is controlled by the myofilaments and the regulatory troponin-tropomyosin complex attached to actin and the myofilaments, actin and myosin (<a href=\"image.htm?imageKey=CARD%2F67388\" class=\"graphic graphic_figure graphicRef67388 \">figure 2</a>). These components can be functionally assessed by the calcium sensitivity and maximal calcium-activated force (Fmax) of fibers rendered hyperpermeable to calcium [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/2\" class=\"abstract_t\">2</a>].</p><p/><p>Abnormal function at any one of these multiple sites can lead to systolic <span class=\"nowrap\">and/or</span> diastolic dysfunction [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/2,4,6\" class=\"abstract_t\">2,4,6</a>]&nbsp;(<a href=\"image.htm?imageKey=CARD%2F74126\" class=\"graphic graphic_figure graphicRef74126 \">figure 5</a>). In particular, diastolic dysfunction can result from excessive calcium entry into the cytosol, a decrease in calcium efflux, or from inadequate calcium reuptake by the sarcoplasmic reticulum during diastole; it does not seem to be due to an excessive calcium influx via slow &quot;L&quot;-type calcium channels [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/7\" class=\"abstract_t\">7</a>]. Support for this comes from a study of myocardial tissue obtained from patients with end-stage congestive heart failure at the time of transplant; diastolic dysfunction occurred in hearts with a decreased sarcoplasmic reticulum calcium ATPase and unchanged sodium-calcium exchange while preserved diastolic function was seen when there was an increased expression of the sodium-calcium exchanger [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/8\" class=\"abstract_t\">8</a>]. Additionally, an animal study found that diastolic function could be improved by adenoviral gene transfer of sarcoplasmic reticulum calcium ATPase [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/9\" class=\"abstract_t\">9</a>].</p><p>Increased intracellular calcium can directly impair diastolic relaxation by persistent activation of the actin-myosin cross-bridge interaction if calcium is not adequately cleared from the cytosol. Excessive calcium may also exert an indirect effect by reducing phosphocreatine and ATP, and increasing adenosine diphosphate (ADP). These indirect effects result from enhanced activity of calcium-activated ATPases, such as the sarcoplasmic reticulum and sarcolemma calcium pumps and other ATPases [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/10\" class=\"abstract_t\">10</a>]. The changes in phosphocreatine (PCr), ATP, and ADP impair myocyte relaxation by causing cross-bridges to lock in a rigor bond position.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Cyclic AMP</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Excitation-contraction coupling in the mammalian heart is modulated by an important second messenger, cyclic adenosine monophosphate (AMP) [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/2\" class=\"abstract_t\">2</a>]. This nucleotide activates a series of protein kinases, which in turn phosphorylate proteins at several subcellular sites, including the sarcolemma, the sarcoplasmic reticulum (SR), and the troponin-tropomyosin regulatory complex on the myofilaments. Phosphorylation of the calcium channels in the sarcolemma increases calcium entry and force generation; phosphorylation of phospholamban on the SR and troponin I on the regulatory complex of the contractile elements enhances calcium resequestration and diastolic relaxation. This important pathway is initiated in vivo by activation of beta 1- and beta 2-adrenergic receptors [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/11\" class=\"abstract_t\">11</a>]. (See <a href=\"topic.htm?path=excitation-contraction-coupling-in-myocardium\" class=\"medical medical_review\">&quot;Excitation-contraction coupling in myocardium&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Other second messengers</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other second messengers in the heart may modulate excitation-contraction coupling. These include inositol triphosphate, which can induce the release of calcium from the sarcoplasmic reticulum, and diacylglycerol, which can activate various enzymatic processes including myosin light chain phosphorylation and sodium-hydrogen exchange (<a href=\"image.htm?imageKey=NEPH%2F70144\" class=\"graphic graphic_figure graphicRef70144 \">figure 6</a>). However, the role of these other second messengers in the heart remains controversial [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/4\" class=\"abstract_t\">4</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Mechanisms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Inotropic and lusitropic mechanisms can be divided into several types [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/12-15\" class=\"abstract_t\">12-15</a>]&nbsp;(<a href=\"image.htm?imageKey=CARD%2F74126\" class=\"graphic graphic_figure graphicRef74126 \">figure 5</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Those that are &quot;upstream&quot; from troponin C and modulate the availability of free calcium ions for activation of the contractile apparatus</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Those that are &quot;downstream&quot; and affect the ability of the myofilaments to respond to any given level of occupancy of the calcium receptor sites on troponin C</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Those that change in the affinity of troponin C for calcium</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Those that change the rate of energy use or supply to the myocytes.</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">ABNORMAL CALCIUM MODULATION IN HEART DISEASE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Abnormal modulation of intracellular calcium has been proposed as a major mechanism underlying the systolic and diastolic dysfunction that develops with cardiac hypertrophy, heart failure, and ischemia [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/2,4\" class=\"abstract_t\">2,4</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Systole</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Systolic force generation is depressed in most models of heart failure, but this change does not always correlate with decreased availability of calcium [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/16-18\" class=\"abstract_t\">16-18</a>]. As an example, in an animal model of right ventricular pressure-overload hypertrophy with failure, systolic force generation is depressed but intracellular calcium levels are normal [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/18\" class=\"abstract_t\">18</a>]. The major abnormality appears to be in the cardiac interstitium where significant changes occur in connective tissue content, which impairs systolic force generation. However, there is an excellent correlation between systolic dysfunction and decreased availability of calcium in cardiac muscle in other animal models of heart failure such as end-stage dilated cardiomyopathy [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/19,20\" class=\"abstract_t\">19,20</a>], diabetes with heart failure [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/21\" class=\"abstract_t\">21</a>], and postmyocardial infarction [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/22\" class=\"abstract_t\">22</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Diastole</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is a highly positive correlation between end-diastolic calcium levels and diastolic relaxation abnormalities. The duration of diastole is prolonged in most models of congestive heart failure, a change that correlates with a prolongation of the intracellular calcium transient [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/16\" class=\"abstract_t\">16</a>]. However, marked increases in systolic and diastolic calcium occur in myocardial ischemia and appear to be uncoupled from force production which falls to very low levels [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/23-25\" class=\"abstract_t\">23-25</a>]. Thus, in ischemia, decreased myofilament calcium responsiveness may affect both systolic force generation and diastolic relaxation.</p><p>In hypertrophic cardiomyopathy, systolic function is normal or hyperdynamic, but diastolic relaxation may become so abnormally slow that complete relaxation between contractions is prevented. At rapid heart rates, this can produce elevated end-diastolic calcium levels and mechanical dysfunction resulting from fusion of the prolonged calcium transients and contractions [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/26,27\" class=\"abstract_t\">26,27</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Heart failure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Three characteristic signatures of congestive heart failure have been consistently noted in physiologic studies of human heart muscle loaded with the calcium indicator aequorin [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/28\" class=\"abstract_t\">28</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An abnormal second component in the calcium signal [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/26\" class=\"abstract_t\">26</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reversal of the normal positive staircase of the force-frequency relationship caused by abnormal calcium restitution processes </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A depressed response to most inotropic agonists that depend upon cyclic adenosine monophosphate (AMP) generation to produce their cellular response [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/29\" class=\"abstract_t\">29</a>]</p><p/><p>Agents that increase intracellular calcium, such as digitalis, exacerbate diastolic functional abnormalities, whereas those that lower intracellular calcium, such as <a href=\"topic.htm?path=verapamil-drug-information\" class=\"drug drug_general\">verapamil</a>, ameliorate them. (See <a href=\"topic.htm?path=treatment-and-prognosis-of-heart-failure-with-preserved-ejection-fraction\" class=\"medical medical_review\">&quot;Treatment and prognosis of heart failure with preserved ejection fraction&quot;</a>.)</p><p>Pharmacologic studies have shown that cyclic AMP levels are depressed in failing human myocardium due to reduced adenylyl cyclase activity; this abnormality may contribute to the alterations in calcium modulation and may be largely responsible for the presence of diastolic relaxation abnormalities [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/29-31\" class=\"abstract_t\">29-31</a>]. Interventions that increase intracellular cyclic AMP concentrations in myopathic human myocardium reverse or significantly ameliorate the diastolic dysfunction that is present [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/27\" class=\"abstract_t\">27</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Ischemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Myocardial ischemia may be associated with a reversible increase in diastolic chamber stiffness both in patients with angina and in experimental models of ischemia [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/32-34\" class=\"abstract_t\">32-34</a>]. Two mechanisms have been proposed as the cause of this increased chamber stiffness, but their relative importance remains controversial:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A rise in intracellular calcium, impaired intracellular reuptake of calcium, and a consequent increase in calcium-activated cross-bridge cycling and tension development [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/23,35-38\" class=\"abstract_t\">23,35-38</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cross-bridges may lock in the rigor state due to a reduction in adenosine triphosphate (ATP) and creatine phosphate levels or an elevation in adenosine diphosphate (ADP) levels [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/39-43\" class=\"abstract_t\">39-43</a>].</p><p/><p>During &quot;demand ischemia,&quot; when myocardial oxygen demand is increased in excess of coronary flow capability (as occurs during stress-induced angina), increased diastolic stiffness appears to be due to rigor-state cross-bridge formation rather than increased calcium-activated diastolic tension [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/44-47\" class=\"abstract_t\">44-47</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">SARCOLEMMAL RECEPTORS AND MECHANISMS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The cardiac sarcolemma is a complex structure that contains multiple receptors (adrenergic and other), channels, exchangers, and pumps that are necessary for maintaining cellular calcium homeostasis (<a href=\"image.htm?imageKey=CARD%2F53118\" class=\"graphic graphic_figure graphicRef53118 \">figure 1</a>). Aspects of normal sarcolemmal function are impaired in the failing heart.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Adrenergic receptors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Both beta-l and beta-2 adrenoceptors, coupled with G proteins, are present in human atrial and ventricular myocardium, and both appear to increase tissue levels of cyclic adenosine monophosphate (AMP) [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/48,49\" class=\"abstract_t\">48,49</a>]. In the nonfailing ventricle, beta-1 receptor density dominates, with the beta-2 and alpha-receptors constituting less than 30 percent of the total [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/50,51\" class=\"abstract_t\">50,51</a>]. In contrast, in the failing heart, there is a selection decrease in the beta-1 fraction by 60 to 70 percent [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/52,53\" class=\"abstract_t\">52,53</a>]. These changes in receptor populations may vary with the etiology of heart failure [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/54\" class=\"abstract_t\">54</a>].</p><p>A third beta-adrenergic receptor (beta-3) is also present in the myocardium [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/55\" class=\"abstract_t\">55</a>]. Activation of this receptor reduces inotropic activity; such an effect could explain in part the improvement in contractility that may be seen with beta blocker therapy in some patients with congestive heart failure. (See <a href=\"topic.htm?path=use-of-beta-blockers-in-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">&quot;Use of beta blockers in heart failure with reduced ejection fraction&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Calcium binding sites</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In contrast to the downregulation of beta -1 adrenergic receptors in heart failure, the calcium antagonist binding sites are not significantly altered in failing left ventricular tissue from patients with idiopathic dilated cardiomyopathy [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/56\" class=\"abstract_t\">56</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Sodium-calcium exchange</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There has been an increasing appreciation that the level of intracellular sodium, acting by means of sodium-calcium exchange, is an important determinant of intracellular calcium (<a href=\"image.htm?imageKey=CARD%2F66739\" class=\"graphic graphic_figure graphicRef66739 \">figure 4</a>) [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/57\" class=\"abstract_t\">57</a>]. The failing heart may be associated with increased intracellular sodium levels due perhaps to reduced activity of the Na-K-ATPase pump that extrudes sodium from the cell. Increased cell sodium decreases the transcellular sodium gradient which drives sodium-calcium exchange; the reduction in sodium-calcium exchange impairs calcium extrusion from the myocardial cell, possibly resulting in prolongation of the action potential and impaired myocyte relaxation [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/58,59\" class=\"abstract_t\">58,59</a>].</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Calcium ATPase</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The calcium ATPase of the cardiac sarcolemma appears to be important for the &quot;fine tuning&quot; of calcium homeostasis [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/60\" class=\"abstract_t\">60</a>]. To date, specific abnormalities associated with dysfunction of this relatively low capacity pump have not been identified.</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Sarcoplasmic reticulum</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The sarcoplasmic reticulum (SR) is the most important intracellular store of calcium in the mammalian heart and plays a primary part in regulating both contraction and relaxation (<a href=\"image.htm?imageKey=CARD%2F62842\" class=\"graphic graphic_figure graphicRef62842 \">figure 7</a>). (See <a href=\"topic.htm?path=excitation-contraction-coupling-in-myocardium\" class=\"medical medical_review\">&quot;Excitation-contraction coupling in myocardium&quot;</a>.) Drugs affecting calcium release and reuptake by the SR have profound effects on diastolic relaxation (<a href=\"image.htm?imageKey=CARD%2F75235\" class=\"graphic graphic_table graphicRef75235 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/61\" class=\"abstract_t\">61</a>]. As an example, caffeine, a complex drug that prolongs contraction and delays relaxation, appears to act predominantly by blocking the ATP-dependent calcium pump of the SR that functions to resequester intracellular calcium.</p><p>Some, but not all, studies have shown decreased calcium uptake rates by the sarcoplasmic reticulum in myopathic human myocardium [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/62\" class=\"abstract_t\">62</a>]. In addition, experimental studies have shown a relative diminution in the density of SR calcium pumps in pressure overload-induced cardiac hypertrophy, an abnormality that could explain the slow velocity of relaxation of severely hypertrophied hearts [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/63\" class=\"abstract_t\">63</a>]. Abnormal calcium modulation by the sarcoplasmic reticulum may contribute to the abnormal frequency-response relationship that is one of the characteristics of failing human myocardium [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/64\" class=\"abstract_t\">64</a>].</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">ALTERED MYOFILAMENT CALCIUM RESPONSIVENESS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cardiac muscle from patients with heart failure of all severities has a lower myofibrillar protein content than muscle from normal hearts [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/65\" class=\"abstract_t\">65</a>]. This observation suggests that a reduction in the amount of myofibrillar protein in ventricular tissue may be a pivotal event in the progression of heart disease to end-stage failure; it may also be related to the development of diastolic dysfunction.</p><p>In addition to changes in calcium availability, cardiac contractility can be regulated by changing the myofilament responsiveness to calcium (<a href=\"image.htm?imageKey=CARD%2F63030\" class=\"graphic graphic_figure graphicRef63030 \">figure 3</a>). Such an effect could occur through altering the affinity of calcium binding to its receptor protein, troponin C, or by some other action on the myofilaments themselves, such as phosphorylation of the myosin light chains or the C proteins of the myosin thick filaments [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/66,67\" class=\"abstract_t\">66,67</a>].</p><p>The applicability of this hypothesis to human disease is uncertain. Several studies have found that end-stage heart failure in humans is not associated with changes in basal myofibrillar calcium sensitivity [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/68-70\" class=\"abstract_t\">68-70</a>]. However, it is possible that the effects of pharmacologic agents on myofibrillar calcium sensitivity can be altered in this setting [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/68\" class=\"abstract_t\">68</a>].</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h1\">ALTERATION OF EXCITATION-CONTRACTION AND REPOLARIZATION-RELAXATION COUPLING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Analysis of the excitation-contraction and repolarization-relaxation coupling pathways predicts that alterations which increase diastolic cytosolic calcium levels may cause diastolic dysfunction because of persistent calcium-activated tension throughout diastole. Conversely, interventions that reduce diastolic cytosolic calcium levels should have a positive lusitropic effect and the potential to ameliorate diastolic dysfunction.</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Role of adenosine triphosphate</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The beginning of an ischemic or hypoxic contracture is associated with a fall of cell adenosine triphosphate (ATP) below a critical level. Such a decrease in ATP availability, which causes actin-myosin crossbridges to &quot;lock&quot; in a noncycling rigor state, was proposed as the mechanism for the initiation of increased diastolic chamber stiffness [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/40,71\" class=\"abstract_t\">40,71</a>]. Support for this comes from a study in which magnetic resonance imaging and phosphorous-31 magnetic resonance spectroscopy were performed at rest and during <a href=\"topic.htm?path=dobutamine-drug-information\" class=\"drug drug_general\">dobutamine</a> stress testing in 24 patients with and without hypertension [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/72\" class=\"abstract_t\">72</a>]. Compared to normal controls, patients with hypertension showed significant alterations at rest in high energy phosphate metabolism with a decrease in creatine kinase activity, a lower total creatine content, and an increase in intracellular inorganic phosphate levels; these changes, which correlated with impaired diastolic function, are similar to what is seen in the normal human heart during severe myocardial stress.</p><p>ATP availability can influence the rate and extent of myocardial relaxation in several ways (<a href=\"image.htm?imageKey=CARD%2F78403\" class=\"graphic graphic_figure graphicRef78403 \">figure 8</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>ATP is required to fuel the ion pumps that directly remove calcium from the cytosol during diastole: the sarcoplasmic reticular calcium- ATPase; and the sarcolemmal calcium extrusion pump (sarcolemmal calcium-ATPase)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>ATP provides energy for the sarcolemmal sodium pump (Na-K-ATPase). An active sodium pump is critical for achieving myocyte relaxation because the intracellular sodium concentration regulates intracellular calcium levels via sarcolemmal sodium-calcium exchange.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>ATP influences myocardial relaxation directly at the level of the myofilaments by interacting with actomyosin to cause its dissociation to actin and myosin, a step critical to relaxation (<a href=\"image.htm?imageKey=CARD%2F51291\" class=\"graphic graphic_figure graphicRef51291 \">figure 9</a>).</p><p/><p>The interaction of ATP with the contractile proteins is complex because ATP has a dual role, being required for both contraction and relaxation. If there is a small amount of ATP depletion, actin-myosin complexes can still form because of the high affinity of the myosin head for ATP, but the dissociation of actin and myosin is reduced since this requires higher concentrations of ATP. Thus, the initial net effect of ATP depletion is to cause inadequate relaxation or diastolic dysfunction. In addition, there is a synergistic interaction between ATP depletion and an elevation in cytosolic calcium to promote diastolic dysfunction (<a href=\"image.htm?imageKey=CARD%2F74126\" class=\"graphic graphic_figure graphicRef74126 \">figure 5</a>).</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h2\">Role of glycolysis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Further evidence that altered ATP levels have a critical role in causing ischemic diastolic dysfunction comes from studies of ischemic glycolysis. During conditions of oxygen supply limitation such as ischemia, the glycolytic pathway becomes a relatively more important source of ATP synthesis because of its ability to achieve ATP synthesis anaerobically. In general, the rate of development of ischemic contracture or diastolic dysfunction is inversely related to the activity of the glycolytic pathway [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/73-76\" class=\"abstract_t\">73-76</a>].</p><p>Glycolysis also plays an important role in the diastolic function of certain forms of pressure-overload hypertrophy. Inhibition of glycolysis in hypertrophied hearts resulted in a much greater impairment of diastolic relaxation than in controls [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/77,78\" class=\"abstract_t\">77,78</a>]. On the other hand, the exaggerated ischemic diastolic chamber stiffness in hypertrophied hearts can be attenuated by providing abundant glycolytic substrate [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/79\" class=\"abstract_t\">79</a>].</p><p>These results are consistent with the hypothesis that the glycolytic pathway may provide a small but critically localized pool of ATP, which may have a high turnover rate relative to its pool size [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/80\" class=\"abstract_t\">80</a>]. Provision of glucose to rat hearts during low-flow ischemia protects against ischemic diastolic dysfunction; this effect is associated with enhanced sarcolemmal Na-K-ATPase activity which prevents an increase in intracellular sodium during ischemia [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/10\" class=\"abstract_t\">10</a>]. Since intracellular sodium excess can lead to cell calcium accumulation (due to reduced sodium-calcium exchange), glucose probably also protected against calcium overload.</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h2\">Digitalis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Digitalis glycosides inhibit the sarcolemmal sodium-potassium ATPase pump, causing an increase in intracellular sodium and ultimately an increase in intracellular calcium via the mechanism described above. The elevation in intracellular calcium is believed to be responsible for the positive inotropic effect of the digitalis glycosides but can also cause diastolic dysfunction due to diastolic cytosolic calcium overload. This is most likely to occur when diastolic calcium removal is impaired, as with hypoxia or ischemia [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/81,82\" class=\"abstract_t\">81,82</a>], or when the myocyte is under an additional cation load during tachycardia.</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h2\">Beta-adrenergic stimulation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Appropriate manipulation of excitation-contraction and repolarization-relaxation coupling can significantly improve hypoxic diastolic function [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/83\" class=\"abstract_t\">83</a>]. The beta-adrenergic agonist <a href=\"topic.htm?path=isoproterenol-drug-information\" class=\"drug drug_general\">isoproterenol</a> exerts its inotropic effect by increasing systolic calcium availability due to an increase in calcium entry via the sarcolemmal calcium channel; its lusitropic action is caused by both an enhanced rate of sarcoplasmic reticulum (SR) calcium reuptake by a phospholamban-mediated mechanism, and reduced troponin sensitivity to calcium.</p><p>The simultaneous administration of the calcium channel blocker <a href=\"topic.htm?path=diltiazem-drug-information\" class=\"drug drug_general\">diltiazem</a> at a dose that blocks the inotropic effect of <a href=\"topic.htm?path=isoproterenol-drug-information\" class=\"drug drug_general\">isoproterenol</a> does not alter its lusitropic actions. This combination regimen results in a net lusitropic effect, increasing both the rate and extent of left ventricular relaxation with and without hypoxia, partially eliminating the exaggerated hypoxic diastolic dysfunction associated with ventricular hypertrophy [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/83\" class=\"abstract_t\">83</a>].</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h2\">Role of angiotensin II and angiotensin converting enzyme inhibition</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Serum angiotensin II concentrations are increased in congestive heart failure, and therapy with angiotensin converting enzyme (ACE) inhibitors improves heart failure symptoms and increases survival. The benefit of ACE inhibition has been attributed to diminished angiotensin II effect on the peripheral circulation, reducing systemic vascular resistance and therefore afterload. Angiotensin II also may directly impair myocardial relaxation, especially in the setting of hypertrophy <span class=\"nowrap\">and/or</span> ischemia. Reversal of this effect with ACE inhibitors or angiotensin II receptor antagonists may be an important mechanism of benefit in patients with heart failure. (See <a href=\"topic.htm?path=angiotensin-converting-enzyme-inhibitors-and-receptor-blockers-in-heart-failure-mechanisms-of-action\" class=\"medical medical_review\">&quot;Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action&quot;</a>.)</p><p>In addition to systemic activation of the renin-angiotensin system, there is now substantial evidence supporting the presence of an endogenous renin-angiotensin system in the heart which may contribute to the development of diastolic dysfunction [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/84-86\" class=\"abstract_t\">84-86</a>]. As an example, the following observations have been made in hypertrophied hearts:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An infusion of angiotensin I resulted in an immediate impairment in diastolic relaxation which was not observed in nonhypertrophied hearts [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/86\" class=\"abstract_t\">86</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>They have a greater capacity to convert angiotensin I to angiotensin II [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/86\" class=\"abstract_t\">86</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>They show exaggerated diastolic dysfunction during low-flow ischemia and a greater degree of ischemic diastolic dysfunction in response after exposure to angiotensin II [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/87\" class=\"abstract_t\">87</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An ACE inhibitor significantly reduces the ischemia-mediated exaggeration in diastolic dysfunction in the hypertrophied, but not the nonhypertrophied, heart [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/87\" class=\"abstract_t\">87</a>].</p><p/><p>Angiotensin II also has a deleterious effect on ischemic diastolic function in the absence of hypertrophy [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/37\" class=\"abstract_t\">37</a>].</p><p>The mechanisms by which angiotensin II impairs myocardial relaxation are not completely defined. In one study, the induction of ischemic diastolic dysfunction was independent of changes of ATP levels, glycolytic rate, or ischemic coronary blood flow [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/37\" class=\"abstract_t\">37</a>]. The most important effects may be an elevation in intracellular pH and enhanced myofilament sensitivity to calcium. (See <a href=\"topic.htm?path=actions-of-angiotensin-ii-on-the-heart\" class=\"medical medical_review\">&quot;Actions of angiotensin II on the heart&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h1\">ROLE OF TITIN IN DIASTOLIC FUNCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Titin is a giant myocyte protein that spans half the sarcomere and plays two critical roles in diastolic function: a recoil spring mechanism and a desensitizer of the myofilaments to calcium.</p><p>Titin is compressed when the myocyte shortens during systole. At the beginning of cell relaxation, when the actin-myosin crossbridges detach and active shortening tension begins to dissipate, the compressed titin forcefully expands and generates an intracellular &quot;restoring force&quot; that relengthens the sarcomere and myocyte [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/88\" class=\"abstract_t\">88</a>]. This restoring force creates a substantial early diastolic ventricular elastic recoil that generates a negative LV pressure that sucks blood across the mitral valve and facilitates LV filling at low LV and left atrial diastolic (filling) pressures [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/89\" class=\"abstract_t\">89</a>].</p><p>The early diastolic elastic recoil is amplified during exercise when greater systolic myocyte shortening causes greater titin compression; this is a critical mechanism that enhances LV diastolic filling during exercise without an increase in left atrial and pulmonary capillary pressure [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/90\" class=\"abstract_t\">90</a>].</p><p>In addition to acting as a recoil spring, titin, in its compressed state, also interacts with the actin-myosin filament to desensitize it to calcium. Thus, the marked titin compression at end-systole facilitates both the detachment of the actin-myosin crossbridge and cell relengthening by the two additive actions of desensitization and elastic recoil [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/88-90\" class=\"abstract_t\">88-90</a>].</p><p>Mutations in the titin gene have been associated with a familial dilated cardiomyopathy [<a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/91\" class=\"abstract_t\">91</a>]. (See <a href=\"topic.htm?path=genetics-of-dilated-cardiomyopathy#H685023\" class=\"medical medical_review\">&quot;Genetics of dilated cardiomyopathy&quot;, section on 'Sarcomere genes'</a>.)</p><p>These data regarding titan serve as an example of how cellular and molecular research is modifying our understanding of cardiac structure and function. This may facilitate the development of novel approaches to reverse diastolic dysfunction in patients, which to date have been few in number and in general palliative rather than curative.</p><p class=\"headingAnchor\" id=\"H30857764\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diastolic dysfunction is caused by structural and functional abnormalities. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Alterations in excitation-contraction coupling can have positive or negative inotropic effects. Alterations in repolarization-relaxation coupling can have positive or negative lusitropic (relaxation-enhancing) effects. (See <a href=\"#H2\" class=\"local\">'Excitation-contraction and repolarization-relaxation coupling'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Abnormal modulation of intracellular calcium has been proposed as a major mechanism underlying systolic and diastolic dysfunction occurring with cardiac hypertrophy, heart failure, and ischemia. (See <a href=\"#H7\" class=\"local\">'Abnormal calcium modulation in heart disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The cardiac sarcolemma is a complex structure that contains multiple receptors (adrenergic and other), channels, exchangers, and pumps that are necessary for maintaining cellular calcium homeostasis (<a href=\"image.htm?imageKey=CARD%2F53118\" class=\"graphic graphic_figure graphicRef53118 \">figure 1</a>). Aspects of normal sarcolemmal function are impaired in the failing heart. (See <a href=\"#H12\" class=\"local\">'Sarcolemmal receptors and mechanisms'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cardiac muscle from patients with heart failure of all severities has a lower myofibrillar protein content than muscle from normal hearts. This observation suggests that a reduction in the amount of myofibrillar protein in ventricular tissue may be a pivotal event in the progression of heart disease to end-stage failure; it may also be related to the development of diastolic dysfunction. (See <a href=\"#H18\" class=\"local\">'Altered myofilament calcium responsiveness'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Alterations that increase diastolic cytosolic calcium levels may cause diastolic dysfunction because of persistent calcium-activated tension throughout diastole. Conversely, interventions that reduce diastolic cytosolic calcium levels should have a positive lusitropic effect and the potential to ameliorate diastolic dysfunction. (See <a href=\"#H19\" class=\"local\">'Alteration of excitation-contraction and repolarization-relaxation coupling'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Titin is a giant myocyte protein that spans half of the sarcomere and plays two critical roles in diastolic function: a recoil spring mechanism and a desensitizer of the myofilaments to calcium. (See <a href=\"#H25\" class=\"local\">'Role of titin in diastolic function'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/1\" class=\"nounderline abstract_t\">Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 2002; 105:1503.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/2\" class=\"nounderline abstract_t\">Morgan JP. Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. N Engl J Med 1991; 325:625.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/3\" class=\"nounderline abstract_t\">Periasamy M, Janssen PM. Molecular basis of diastolic dysfunction. Heart Fail Clin 2008; 4:13.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/4\" class=\"nounderline abstract_t\">Cheng H, Lederer MR, Xiao RP, et al. Excitation-contraction coupling in heart: new insights from Ca2+ sparks. Cell Calcium 1996; 20:129.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/5\" class=\"nounderline abstract_t\">Blinks JR, Endoh M. Modification of myofibrillar responsiveness to Ca++ as an inotropic mechanism. Circulation 1986; 73:III85.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/6\" class=\"nounderline abstract_t\">Katz AM. Interplay between inotropic and lusitropic effects of cyclic adenosine monophosphate on the myocardial cell. Circulation 1990; 82:I7.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/7\" class=\"nounderline abstract_t\">Applegate RJ, Walsh RA, O'Rourke RA. Effects of nifedipine on diastolic function during brief periods of flow-limiting ischemia in the conscious dog. Circulation 1987; 76:1409.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/8\" class=\"nounderline abstract_t\">Hasenfuss G, Schillinger W, Lehnart SE, et al. Relationship between Na+-Ca2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation 1999; 99:641.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/9\" class=\"nounderline abstract_t\">Schmidt U, del Monte F, Miyamoto MI, et al. Restoration of diastolic function in senescent rat hearts through adenoviral gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase. Circulation 2000; 101:790.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/10\" class=\"nounderline abstract_t\">Cross HR, Radda GK, Clarke K. The role of Na+/K+ ATPase activity during low flow ischemia in preventing myocardial injury: a 31P, 23Na and 87Rb NMR spectroscopic study. Magn Reson Med 1995; 34:673.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/11\" class=\"nounderline abstract_t\">Kaumann A, Bartel S, Molenaar P, et al. Activation of beta2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure. Circulation 1999; 99:65.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/12\" class=\"nounderline abstract_t\">Katz AM. Energy requirements of contraction and relaxation: implications for inotropic stimulation of the failing heart. Basic Res Cardiol 1989; 84 Suppl 1:47.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/13\" class=\"nounderline abstract_t\">Hein S, Schaper J. Pathogenesis of dilated cardiomyopathy and heart failure: insights from cell morphology and biology. Curr Opin Cardiol 1996; 11:293.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/14\" class=\"nounderline abstract_t\">Wagoner LE, Walsh RA. The cellular pathophysiology of progression to heart failure. Curr Opin Cardiol 1996; 11:237.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/15\" class=\"nounderline abstract_t\">Davies CH, Harding SE, Poole-Wilson PA. Cellular mechanisms of contractile dysfunction in human heart failure. Eur Heart J 1996; 17:189.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/16\" class=\"nounderline abstract_t\">Perreault CL, Bing OH, Brooks WW, et al. Differential effects of cardiac hypertrophy and failure on right versus left ventricular calcium activation. Circ Res 1990; 67:707.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/17\" class=\"nounderline abstract_t\">Perreault CL, Hague NL, Ransil BJ, Morgan JP. The effects of cocaine on intracellular Ca2+ handling and myofilament Ca2+ responsiveness of ferret ventricular myocardium. Br J Pharmacol 1990; 101:679.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/18\" class=\"nounderline abstract_t\">Gwathmey JK, Morgan JP. Altered calcium handling in experimental pressure-overload hypertrophy in the ferret. Circ Res 1985; 57:836.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/19\" class=\"nounderline abstract_t\">Bentivegna LA, Ablin LW, Kihara Y, Morgan JP. Altered calcium handling in left ventricular pressure-overload hypertrophy as detected with aequorin in the isolated, perfused ferret heart. Circ Res 1991; 69:1538.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/20\" class=\"nounderline abstract_t\">Wikman-Coffelt J, Stefenelli T, Wu ST, et al. [Ca2+]i transients in the cardiomyopathic hamster heart. Circ Res 1991; 68:45.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/21\" class=\"nounderline abstract_t\">Belke DD, Dillmann WH. Altered cardiac calcium handling in diabetes. Curr Hypertens Rep 2004; 6:424.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/22\" class=\"nounderline abstract_t\">Litwin SE, Morgan JP. Captopril enhances intracellular calcium handling and beta-adrenergic responsiveness of myocardium from rats with postinfarction failure. Circ Res 1992; 71:797.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/23\" class=\"nounderline abstract_t\">Kihara Y, Grossman W, Morgan JP. Direct measurement of changes in intracellular calcium transients during hypoxia, ischemia, and reperfusion of the intact mammalian heart. Circ Res 1989; 65:1029.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/24\" class=\"nounderline abstract_t\">Mohabir R, Lee HC, Kurz RW, Clusin WT. Effects of ischemia and hypercarbic acidosis on myocyte calcium transients, contraction, and pHi in perfused rabbit hearts. Circ Res 1991; 69:1525.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/25\" class=\"nounderline abstract_t\">Steenbergen C, Murphy E, Levy L, London RE. Elevation in cytosolic free calcium concentration early in myocardial ischemia in perfused rat heart. Circ Res 1987; 60:700.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/26\" class=\"nounderline abstract_t\">Gwathmey JK, Copelas L, MacKinnon R, et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 1987; 61:70.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/27\" class=\"nounderline abstract_t\">Gwathmey JK, Warren SE, Briggs GM, et al. Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole. J Clin Invest 1991; 87:1023.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/28\" class=\"nounderline abstract_t\">Hasenfuss G, Reinecke H, Studer R, et al. Calcium cycling proteins and force-frequency relationship in heart failure. Basic Res Cardiol 1996; 91 Suppl 2:17.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/29\" class=\"nounderline abstract_t\">Feldman MD, Copelas L, Gwathmey JK, et al. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 1987; 75:331.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/30\" class=\"nounderline abstract_t\">Erdmann E. The effectiveness of inotropic agents in isolated cardiac preparations from the human heart. Klin Wochenschr 1988; 66:1.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/31\" class=\"nounderline abstract_t\">N&auml;bauer M, B&ouml;hm M, Brown L, et al. Positive inotropic effects in isolated ventricular myocardium from non-failing and terminally failing human hearts. Eur J Clin Invest 1988; 18:600.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/32\" class=\"nounderline abstract_t\">Fifer MA, Bourdillon PD, Lorell BH. Altered left ventricular diastolic properties during pacing-induced angina in patients with aortic stenosis. Circulation 1986; 74:675.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/33\" class=\"nounderline abstract_t\">Carroll JD, Hess OM, Hirzel HO, Krayenbuehl HP. Exercise-induced ischemia: the influence of altered relaxation on early diastolic pressures. Circulation 1983; 67:521.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/34\" class=\"nounderline abstract_t\">Bronzwaer JG, de Bruyne B, Ascoop CA, Paulus WJ. Comparative effects of pacing-induced and balloon coronary occlusion ischemia on left ventricular diastolic function in man. Circulation 1991; 84:211.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/35\" class=\"nounderline abstract_t\">Apstein CS, Grossman W. Opposite initial effects of supply and demand ischemia on left ventricular diastolic compliance: the ischemia-diastolic paradox. J Mol Cell Cardiol 1987; 19:119.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/36\" class=\"nounderline abstract_t\">Eberli FR, Weinberg EO, Grice WN, et al. Protective effect of increased glycolytic substrate against systolic and diastolic dysfunction and increased coronary resistance from prolonged global underperfusion and reperfusion in isolated rabbit hearts perfused with erythrocyte suspensions. Circ Res 1991; 68:466.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/37\" class=\"nounderline abstract_t\">Mochizuki T, Eberli FR, Apstein CS, Lorell BH. Exacerbation of ischemic dysfunction by angiotensin II in red cell-perfused rabbit hearts. Effects on coronary flow, contractility, and high-energy phosphate metabolism. J Clin Invest 1992; 89:490.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/38\" class=\"nounderline abstract_t\">Wexler LF, Weinberg EO, Ingwall JS, Apstein CS. Acute alterations in diastolic left ventricular chamber distensibility: mechanistic differences between hypoxemia and ischemia in isolated perfused rabbit and rat hearts. Circ Res 1986; 59:515.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/39\" class=\"nounderline abstract_t\">Katz AM, Tada M. The &quot;stone heart&quot;: a challenge to the biochemist. Am J Cardiol 1972; 29:578.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/40\" class=\"nounderline abstract_t\">Hearse DJ, Garlick PB, Humphrey SM. Ischemic contracture of the myocardium: mechanisms and prevention. Am J Cardiol 1977; 39:986.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/41\" class=\"nounderline abstract_t\">Ventura-Clapier R, Veksler V. Myocardial ischemic contracture. Metabolites affect rigor tension development and stiffness. Circ Res 1994; 74:920.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/42\" class=\"nounderline abstract_t\">Yamashita H, Sata M, Sugiura S, et al. ADP inhibits the sliding velocity of fluorescent actin filaments on cardiac and skeletal myosins. Circ Res 1994; 74:1027.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/43\" class=\"nounderline abstract_t\">Tian R, Christe ME, Spindler M, et al. Role of MgADP in the development of diastolic dysfunction in the intact beating rat heart. J Clin Invest 1997; 99:745.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/44\" class=\"nounderline abstract_t\">Varma N, Eberli FR, Apstein CS. Increased diastolic chamber stiffness during demand ischemia: response to quick length change differentiates rigor-activated from calcium-activated tension. Circulation 2000; 101:2185.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/45\" class=\"nounderline abstract_t\">Eberli FR, Str&ouml;mer H, Ferrell MA, et al. Lack of direct role for calcium in ischemic diastolic dysfunction in isolated hearts. Circulation 2000; 102:2643.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/46\" class=\"nounderline abstract_t\">Varma N, Eberli FR, Apstein CS. Left ventricular diastolic dysfunction during demand ischemia: rigor underlies increased stiffness without calcium-mediated tension. Amelioration by glycolytic substrate. J Am Coll Cardiol 2001; 37:2144.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/47\" class=\"nounderline abstract_t\">Varma N, Morgan JP, Apstein CS. Mechanisms underlying ischemic diastolic dysfunction: relation between rigor, calcium homeostasis, and relaxation rate. Am J Physiol Heart Circ Physiol 2003; 284:H758.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/48\" class=\"nounderline abstract_t\">Lefkowitz RJ, Hausdorff WP, Caron MG. Role of phosphorylation in desensitization of the beta-adrenoceptor. Trends Pharmacol Sci 1990; 11:190.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/49\" class=\"nounderline abstract_t\">Collins S, Bolanowski MA, Caron MG, Lefkowitz RJ. Genetic regulation of beta-adrenergic receptors. Annu Rev Physiol 1989; 51:203.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/50\" class=\"nounderline abstract_t\">Brodde OE. Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 1991; 43:203.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/51\" class=\"nounderline abstract_t\">Bristow MR, Hershberger RE, Port JD, et al. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990; 82:I12.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/52\" class=\"nounderline abstract_t\">Bristow MR, Ginsburg R, Umans V, et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986; 59:297.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/53\" class=\"nounderline abstract_t\">Altschuld RA, Starling RC, Hamlin RL, et al. Response of failing canine and human heart cells to beta 2-adrenergic stimulation. Circulation 1995; 92:1612.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/54\" class=\"nounderline abstract_t\">Bristow MR, Anderson FL, Port JD, et al. Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991; 84:1024.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/55\" class=\"nounderline abstract_t\">Gauthier C, Tavernier G, Charpentier F, et al. Functional beta3-adrenoceptor in the human heart. J Clin Invest 1996; 98:556.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/56\" class=\"nounderline abstract_t\">Rasmussen RP, Minobe W, Bristow MR. Calcium antagonist binding sites in failing and nonfailing human ventricular myocardium. Biochem Pharmacol 1990; 39:691.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/57\" class=\"nounderline abstract_t\">Kaczorowski GJ, Slaughter RS, King VF, Garcia ML. Inhibitors of sodium-calcium exchange: identification and development of probes of transport activity. Biochim Biophys Acta 1989; 988:287.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/58\" class=\"nounderline abstract_t\">Schouten VJ, ter Keurs HE, Quaegebeur JM. Influence of electrogenic Na/Ca exchange on the action potential in human heart muscle. Cardiovasc Res 1990; 24:758.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/59\" class=\"nounderline abstract_t\">Wankerl M, Schwartz K. Calcium transport proteins in the nonfailing and failing heart: gene expression and function. J Mol Med (Berl) 1995; 73:487.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/60\" class=\"nounderline abstract_t\">Caroni P, Carafoli E. An ATP-dependent Ca2+-pumping system in dog heart sarcolemma. Nature 1980; 283:765.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/61\" class=\"nounderline abstract_t\">Sutko JL, Ito K, Kenyon JL. Ryanodine: a modifier of sarcoplasmic reticulum calcium release in striated muscle. Fed Proc 1985; 44:2984.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/62\" class=\"nounderline abstract_t\">Dillmann WH. Regulation of expression of cardiac sarcoplasmic reticulum proteins under pathophysiological conditions. Mol Cell Biochem 1996; 157:125.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/63\" class=\"nounderline abstract_t\">de la Bastie D, Levitsky D, Rappaport L, et al. Function of the sarcoplasmic reticulum and expression of its Ca2(+)-ATPase gene in pressure overload-induced cardiac hypertrophy in the rat. Circ Res 1990; 66:554.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/64\" class=\"nounderline abstract_t\">Gwathmey JK, Slawsky MT, Hajjar RJ, et al. Role of intracellular calcium handling in force-interval relationships of human ventricular myocardium. J Clin Invest 1990; 85:1599.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/65\" class=\"nounderline abstract_t\">ter Keurs HE. Heart failure and Starling's Law of the heart. Can J Cardiol 1996; 12:1047.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/66\" class=\"nounderline abstract_t\">R&uuml;egg JC, Morano I. Calcium-sensitivity modulation of cardiac myofibrillar proteins. J Cardiovasc Pharmacol 1989; 14 Suppl 3:S20.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/67\" class=\"nounderline abstract_t\">Morano I, Arndt H, G&auml;rtner C, R&uuml;egg JC. Skinned fibers of human atrium and ventricle: myosin isoenzymes and contractility. Circ Res 1988; 62:632.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/68\" class=\"nounderline abstract_t\">Hajjar RJ, Gwathmey JK, Briggs GM, Morgan JP. Differential effect of DPI 201-106 on the sensitivity of the myofilaments to Ca2+ in intact and skinned trabeculae from control and myopathic human hearts. J Clin Invest 1988; 82:1578.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/69\" class=\"nounderline abstract_t\">Wankerl M, B&ouml;hm M, Morano I, et al. Calcium sensitivity and myosin light chain pattern of atrial and ventricular skinned cardiac fibers from patients with various kinds of cardiac disease. J Mol Cell Cardiol 1990; 22:1425.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/70\" class=\"nounderline abstract_t\">D'Agnolo A, Luciani GB, Mazzucco A, et al. Contractile properties and Ca2+ release activity of the sarcoplasmic reticulum in dilated cardiomyopathy. Circulation 1992; 85:518.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/71\" class=\"nounderline abstract_t\">Lowe JE, Jennings RB, Reimer KA. Cardiac rigor mortis in dogs. J Mol Cell Cardiol 1979; 11:1017.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/72\" class=\"nounderline abstract_t\">Lamb HJ, Beyerbacht HP, van der Laarse A, et al. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 1999; 99:2261.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/73\" class=\"nounderline abstract_t\">Apstein CS, Deckelbaum L, Hagopian L, Hood WB Jr. Acute cardiac ischemia and reperfusion: contractility, relaxation, and glycolysis. Am J Physiol 1978; 235:H637.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/74\" class=\"nounderline abstract_t\">Apstein CS, Gravino FN, Haudenschild CC. Determinants of a protective effect of glucose and insulin on the ischemic myocardium. Effects on contractile function, diastolic compliance, metabolism, and ultrastructure during ischemia and reperfusion. Circ Res 1983; 52:515.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/75\" class=\"nounderline abstract_t\">Schaefer S, Prussel E, Carr LJ. Requirement of glycolytic substrate for metabolic recovery during moderate low flow ischemia. J Mol Cell Cardiol 1995; 27:2167.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/76\" class=\"nounderline abstract_t\">Vanoverschelde JL, Janier MF, Bakke JE, et al. Rate of glycolysis during ischemia determines extent of ischemic injury and functional recovery after reperfusion. Am J Physiol 1994; 267:H1785.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/77\" class=\"nounderline abstract_t\">Kagaya Y, Weinberg EO, Ito N, et al. Glycolytic inhibition: effects on diastolic relaxation and intracellular calcium handling in hypertrophied rat ventricular myocytes. J Clin Invest 1995; 95:2766.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/78\" class=\"nounderline abstract_t\">Tian R, Nascimben L, Ingwall JS, Lorell BH. Failure to maintain a low ADP concentration impairs diastolic function in hypertrophied rat hearts. Circulation 1997; 96:1313.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/79\" class=\"nounderline abstract_t\">Cunningham MJ, Apstein CS, Weinberg EO, et al. Influence of glucose and insulin on the exaggerated diastolic and systolic dysfunction of hypertrophied rat hearts during hypoxia. Circ Res 1990; 66:406.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/80\" class=\"nounderline abstract_t\">Weiss J, Hiltbrand B. Functional compartmentation of glycolytic versus oxidative metabolism in isolated rabbit heart. J Clin Invest 1985; 75:436.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/81\" class=\"nounderline abstract_t\">Cunningham MJ, Apstein CS, Weinberg EO, Lorell BH. Deleterious effect of ouabain on myocardial function during hypoxia. Am J Physiol 1989; 256:H681.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/82\" class=\"nounderline abstract_t\">Lorell BH, Isoyama S, Grice WN, et al. Effects of ouabain and isoproterenol on left ventricular diastolic function during low-flow ischemia in isolated, blood-perfused rabbit hearts. Circ Res 1988; 63:457.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/83\" class=\"nounderline abstract_t\">Weinberg EO, Apstein CS, Vogel WM. Impaired myocardial relaxation is improved by combined beta-adrenergic stimulation and calcium channel blockade. J Mol Cell Cardiol 1991; 23:S68.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/84\" class=\"nounderline abstract_t\">Raman VK, Lee YA, Lindpaintner K. The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy. Am J Cardiol 1995; 76:18D.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/85\" class=\"nounderline abstract_t\">Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993; 153:937.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/86\" class=\"nounderline abstract_t\">Schunkert H, Dzau VJ, Tang SS, et al. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J Clin Invest 1990; 86:1913.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/87\" class=\"nounderline abstract_t\">Eberli FR, Apstein CS, Ngoy S, Lorell BH. Exacerbation of left ventricular ischemic diastolic dysfunction by pressure-overload hypertrophy. Modification by specific inhibition of cardiac angiotensin converting enzyme. Circ Res 1992; 70:931.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/88\" class=\"nounderline abstract_t\">Helmes M, Trombit&aacute;s K, Granzier H. Titin develops restoring force in rat cardiac myocytes. Circ Res 1996; 79:619.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/89\" class=\"nounderline abstract_t\">Helmes M, Lim CC, Liao R, et al. Titin determines the Frank-Starling relation in early diastole. J Gen Physiol 2003; 121:97.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/90\" class=\"nounderline abstract_t\">Cheng CP, Noda T, Nozawa T, Little WC. Effect of heart failure on the mechanism of exercise-induced augmentation of mitral valve flow. Circ Res 1993; 72:795.</a></li><li><a href=\"https://www.uptodate.com/contents/cellular-mechanisms-of-diastolic-dysfunction/abstract/91\" class=\"nounderline abstract_t\">Gerull B, Gramlich M, Atherton J, et al. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat Genet 2002; 30:201.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3463 Version 5.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H30857764\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EXCITATION-CONTRACTION AND REPOLARIZATION-RELAXATION COUPLING</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Role of calcium</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Cyclic AMP</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Other second messengers</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Mechanisms</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">ABNORMAL CALCIUM MODULATION IN HEART DISEASE</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">Systole</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Diastole</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Heart failure</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Ischemia</a></li></ul></li><li><a href=\"#H12\" id=\"outline-link-H12\">SARCOLEMMAL RECEPTORS AND MECHANISMS</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">Adrenergic receptors</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Calcium binding sites</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Sodium-calcium exchange</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Calcium ATPase</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Sarcoplasmic reticulum</a></li></ul></li><li><a href=\"#H18\" id=\"outline-link-H18\">ALTERED MYOFILAMENT CALCIUM RESPONSIVENESS</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">ALTERATION OF EXCITATION-CONTRACTION AND REPOLARIZATION-RELAXATION COUPLING</a><ul><li><a href=\"#H20\" id=\"outline-link-H20\">Role of adenosine triphosphate</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">Role of glycolysis</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">Digitalis</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">Beta-adrenergic stimulation</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">Role of angiotensin II and angiotensin converting enzyme inhibition</a></li></ul></li><li><a href=\"#H25\" id=\"outline-link-H25\">ROLE OF TITIN IN DIASTOLIC FUNCTION</a></li><li><a href=\"#H30857764\" id=\"outline-link-H30857764\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"CARD/3463|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=CARD/79802\" class=\"graphic graphic_algorithm\">- Cell mechanism diastol dysfunct</a></li></ul></li><li><div id=\"CARD/3463|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/53118\" class=\"graphic graphic_figure\">- Regulation sarcolemma function</a></li><li><a href=\"image.htm?imageKey=CARD/67388\" class=\"graphic graphic_figure\">- Troponin tropomyosin complex</a></li><li><a href=\"image.htm?imageKey=CARD/63030\" class=\"graphic graphic_figure\">- Changes calcium sensitivity</a></li><li><a href=\"image.htm?imageKey=CARD/66739\" class=\"graphic graphic_figure\">- Excitation contraction</a></li><li><a href=\"image.htm?imageKey=CARD/74126\" class=\"graphic graphic_figure\">- Regulation contractile state</a></li><li><a href=\"image.htm?imageKey=NEPH/70144\" class=\"graphic graphic_figure\">- Phosphatidylinositol turnover</a></li><li><a href=\"image.htm?imageKey=CARD/62842\" class=\"graphic graphic_figure\">- Regulation SR function</a></li><li><a href=\"image.htm?imageKey=CARD/78403\" class=\"graphic graphic_figure\">- Contraction relaxation cycle</a></li><li><a href=\"image.htm?imageKey=CARD/51291\" class=\"graphic graphic_figure\">- Actin myosin interaction</a></li></ul></li><li><div id=\"CARD/3463|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/75235\" class=\"graphic graphic_table\">- Interventions intracell calcium</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=actions-of-angiotensin-ii-on-the-heart\" class=\"medical medical_review\">Actions of angiotensin II on the heart</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=angiotensin-converting-enzyme-inhibitors-and-receptor-blockers-in-heart-failure-mechanisms-of-action\" class=\"medical medical_review\">Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-heart-failure-with-preserved-ejection-fraction\" class=\"medical medical_review\">Clinical manifestations and diagnosis of heart failure with preserved ejection fraction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=excitation-contraction-coupling-in-myocardium\" class=\"medical medical_review\">Excitation-contraction coupling in myocardium</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=genetics-of-dilated-cardiomyopathy\" class=\"medical medical_review\">Genetics of dilated cardiomyopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathophysiology-of-heart-failure-with-preserved-ejection-fraction\" class=\"medical medical_review\">Pathophysiology of heart failure with preserved ejection fraction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prognosis-of-heart-failure-with-preserved-ejection-fraction\" class=\"medical medical_review\">Treatment and prognosis of heart failure with preserved ejection fraction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=use-of-beta-blockers-in-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">Use of beta blockers in heart failure with reduced ejection fraction</a></li></ul></div></div>","javascript":null}